Your browser doesn't support javascript.
loading
Tuning the Antigen Density Requirement for CAR T-cell Activity.
Majzner, Robbie G; Rietberg, Skyler P; Sotillo, Elena; Dong, Rui; Vachharajani, Vipul T; Labanieh, Louai; Myklebust, June H; Kadapakkam, Meena; Weber, Evan W; Tousley, Aidan M; Richards, Rebecca M; Heitzeneder, Sabine; Nguyen, Sang M; Wiebking, Volker; Theruvath, Johanna; Lynn, Rachel C; Xu, Peng; Dunn, Alexander R; Vale, Ronald D; Mackall, Crystal L.
Affiliation
  • Majzner RG; Department of Pediatrics, Stanford University School of Medicine, Stanford, California.
  • Rietberg SP; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.
  • Sotillo E; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.
  • Dong R; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.
  • Vachharajani VT; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, California.
  • Labanieh L; Biophysics Program, Stanford University, Stanford, California.
  • Myklebust JH; Department of Bioengineering, Stanford University School of Medicine, Stanford, California.
  • Kadapakkam M; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
  • Weber EW; KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.
  • Tousley AM; Department of Pediatrics, Stanford University School of Medicine, Stanford, California.
  • Richards RM; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.
  • Heitzeneder S; Department of Pediatrics, Stanford University School of Medicine, Stanford, California.
  • Nguyen SM; Department of Pediatrics, Stanford University School of Medicine, Stanford, California.
  • Wiebking V; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.
  • Theruvath J; Department of Pediatrics, Stanford University School of Medicine, Stanford, California.
  • Lynn RC; Department of Pediatrics, Stanford University School of Medicine, Stanford, California.
  • Xu P; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.
  • Dunn AR; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.
  • Vale RD; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.
  • Mackall CL; Department of Chemical Engineering, Stanford University, Stanford, California.
Cancer Discov ; 10(5): 702-723, 2020 05.
Article in En | MEDLINE | ID: mdl-32193224
Insufficient reactivity against cells with low antigen density has emerged as an important cause of chimeric antigen receptor (CAR) T-cell resistance. Little is known about factors that modulate the threshold for antigen recognition. We demonstrate that CD19 CAR activity is dependent upon antigen density and that the CAR construct in axicabtagene ciloleucel (CD19-CD28ζ) outperforms that in tisagenlecleucel (CD19-4-1BBζ) against antigen-low tumors. Enhancing signal strength by including additional immunoreceptor tyrosine-based activation motifs (ITAM) in the CAR enables recognition of low-antigen-density cells, whereas ITAM deletions blunt signal and increase the antigen density threshold. Furthermore, replacement of the CD8 hinge-transmembrane (H/T) region of a 4-1BBζ CAR with a CD28-H/T lowers the threshold for CAR reactivity despite identical signaling molecules. CARs incorporating a CD28-H/T demonstrate a more stable and efficient immunologic synapse. Precise design of CARs can tune the threshold for antigen recognition and endow 4-1BBζ-CARs with enhanced capacity to recognize antigen-low targets while retaining a superior capacity for persistence. SIGNIFICANCE: Optimal CAR T-cell activity is dependent on antigen density, which is variable in many cancers, including lymphoma and solid tumors. CD28ζ-CARs outperform 4-1BBζ-CARs when antigen density is low. However, 4-1BBζ-CARs can be reengineered to enhance activity against low-antigen-density tumors while maintaining their unique capacity for persistence.This article is highlighted in the In This Issue feature, p. 627.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Receptors, Chimeric Antigen Limits: Animals / Humans Language: En Journal: Cancer Discov Year: 2020 Document type: Article Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Receptors, Chimeric Antigen Limits: Animals / Humans Language: En Journal: Cancer Discov Year: 2020 Document type: Article Country of publication: